Strengthening the R&D Framework with a Long-Term Perspective
First written in FY2016. 25 of 36 entries say "Restated". Latest entry: 2026-08-10.
2 other companies' latest entry also says "Restated".
- 2026-08-10RestatedEarnings
「There were no material changes in the status of the Group's research and development activities during the cumulative first quarter.」
The Group reaffirms that there were no material changes in its research and development activities. - FY2026AdvancedAnnual report
「In the electronic materials business, the company began mass production in 2024 of CEG® 34E and CEG® 39A etching gases for semiconductors.」
The company reported the start of mass production of 2 new etching-gas products for semiconductors, demonstrating concrete progress from research and development to mass production. R&D expenditure was ¥7,659 million. - 2026-05-14AdvancedEarnings
「The Group’s research and development expenditures during the consolidated cumulative period amounted to ¥7,659 million.」
Research and development expenditures increased from ¥7,390 million in the previous fiscal year to ¥7,659 million. - FY2026-H1RestatedAnnual report
「The Group's R&D expenditure for the interim consolidated accounting period was ¥3,845 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
While stating that there were no material changes in the status of its R&D activities, the company recognized R&D expenditure of ¥3,845 million. - FY2025AdvancedAnnual report
「R&D expenditure for the current consolidated fiscal year was ¥7,390 million. An overview of the main R&D activities and their results is as follows.」
The company recognized R&D expenditure of ¥7,390 million and made concrete progress on R&D in areas including the construction of the Functional Materials Research Building, SiC manufacturing technologies, electronic and energy materials, and life sciences. - FY2025-H1RestatedAnnual report
「The Group's R&D expenditure for the interim consolidated accounting period was ¥3,578 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company continued its R&D activities and recognized R&D expenditure of ¥3,578 million for the interim consolidated accounting period. It stated that there were no material changes in the status of those activities. - FY2024AdvancedAnnual report
「After passing the stage-gate review at the end of fiscal 2023, the project advanced from an NEDO-commissioned project to an NEDO-subsidized project in April 2024.」
Regarding the development of manufacturing technologies for 8-inch SiC single crystals and wafers, the project passed the stage-gate review at the end of fiscal 2023 and changed from an NEDO-commissioned project to an NEDO-subsidized project in April 2024. This represents a specific advance in the R&D process. - FY2024-Q3RestatedAnnual report
「The Group's R&D expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥4,739 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recognized R&D expenditure of ¥4,739 million and stated that there were no material changes in the status of its R&D activities. - FY2024-Q2RestatedAnnual report
「The Group's R&D expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥3,148 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company recognized R&D expenditure of ¥3,148 million and stated that there were no material changes in the status of its R&D activities. - FY2024-Q1RestatedAnnual report
「The Group's R&D expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥1,477 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company recognized R&D expenditure of ¥1,477 million and stated that there were no material changes in the status of its R&D activities. - FY2023AdvancedAnnual report
「Since July 2022, the company has newly promoted R&D through a three-institute structure comprising the Fundamental Chemistry Research Institute, the Functional Chemistry Research Institute, and the New-STEP Research Institute, with the respective roles of creating fundamental technologies, efficiently developing functional materials, and conducting corporate research clearly defined.」
The R&D structure was reorganized into three research institutes. The company also specified R&D facilities and themes, including the Functional Materials Research Building scheduled for completion in fiscal 2024, the Electronic Materials Research Center in Taiwan, and the development of 8-inch SiC manufacturing technologies. - FY2023-Q3RestatedAnnual report
「The Group's R&D expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥4,071 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recognized R&D expenditure of ¥4,071 million and stated that there were no material changes in the status of its R&D activities. - FY2023-Q1RestatedAnnual report
「The Group's R&D expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥1,356 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company recognized R&D expenditure of ¥1,356 million and stated that there were no material changes in the status of its R&D activities. - FY2022AdvancedAnnual report
「In 2021, the company established the Shonan Research Center within Shonan iPark in Fujisawa, Kanagawa Prefecture, and began R&D aimed at creating new businesses. In addition, the company's project to develop manufacturing technologies for high-quality 8-inch SiC single crystals and wafers was selected for NEDO's public solicitation project, the Green Innovation Fund Project: Construction of Next-Generation Digital Infrastructure. The company has begun work toward commencing operations in fiscal 2022.」
It describes specific progress in R&D facilities and themes, including the opening of the Shonan Research Center and the selection and launch of a project to develop manufacturing technologies for new SiC single crystals and wafers. Annual R&D expenditure was ¥5,448 million. - FY2022-Q3RestatedAnnual report
「The Group's R&D expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥4,041 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recognized R&D expenditure of ¥4,041 million and stated that there were no material changes in the status of its R&D activities. - FY2021RestatedAnnual report
「R&D expenditure for the current consolidated fiscal year was ¥5,744 million. An overview of the main R&D activities and their results is as follows.」
The company recognized R&D expenditure of ¥5,744 million and continued R&D on machine learning, semiconductor materials, electrolytes, non-HFC products, and carbon-neutral technologies. - FY2021-Q3RestatedAnnual report
「The Group's R&D expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥4,241 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recognized cumulative third-quarter R&D expenditure of ¥4,241 million and stated that there were no material changes in the status of its R&D activities. - FY2021-Q2RestatedAnnual report
「The Group's R&D expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥2,843 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company recognized R&D expenditure of ¥2,843 million and stated that there were no material changes in the status of its R&D activities. - FY2021-Q1RestatedAnnual report
「The Group's R&D expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥1,403 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company recognized R&D expenditure of ¥1,403 million and stated that there were no material changes in the status of its R&D activities. - FY2020AdvancedAnnual report
「R&D expenditure for the current consolidated fiscal year was ¥5,866 million. An overview of the main R&D activities and their results is as follows.」
The company recognized annual R&D expenditure of ¥5,866 million and continued developing products incorporating machine learning, next-generation secondary-battery materials, pharmaceutical and agrochemical intermediates, and non-HFC products. - FY2020-Q3RestatedAnnual report
「The Group's R&D expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥4,435 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company recognized cumulative third-quarter R&D expenditure of ¥4,435 million and stated that there were no material changes in the status of its R&D activities. - FY2020-Q2RestatedAnnual report
「The Group's R&D expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥2,958 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company recognized cumulative second-quarter R&D expenditure of ¥2,958 million and stated that there were no material changes in the status of its R&D activities. - FY2020-Q1RestatedAnnual report
「The Group's R&D expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥1,464 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company recognized R&D expenditure of ¥1,464 million for the first quarter and stated that there were no material changes in the status of its R&D activities. - FY2019AdvancedAnnual report
「The Third Research Building at the Chemical Research Institute, which began operations in April 2018 to strengthen R&D capabilities, and the Chemical Products Production Technology Center, which began operations in July 2018 to further accelerate the transition from research and development to mass production, have each commenced operations.」
The Third Research Building at the Chemical Research Institute and the Chemical Products Production Technology Center, which were scheduled to begin operations in the previous fiscal year, actually commenced operations in April and July 2018, respectively. - FY2019-Q3RestatedAnnual report
「The Group's R&D expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥4,316 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company continued its R&D activities and recognized R&D expenditure of ¥4,316 million for the cumulative third quarter of the current consolidated fiscal year, while stating that there were no material changes in the status of those activities. - FY2019-Q2RestatedAnnual report
「The Group's R&D expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥2,838 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company continued its R&D activities and recognized cumulative R&D expenditure of ¥2,838 million, while stating that there were no material changes in the status of those activities. - FY2019-Q1RestatedAnnual report
「The Group's R&D expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥1,339 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company continued its R&D activities and reported R&D expenditure of ¥1,339 million for the cumulative quarter, stating that there were no material changes in the status of those activities. - FY2018AdvancedAnnual report
「The Third Research Building at the Chemical Research Institute, scheduled to begin operations in April 2018 to strengthen R&D capabilities, and the Production Technology Center, scheduled to begin operations in summer 2018 to further accelerate the transition from research and development to mass production, will each commence operations.」
It describes specific progress at the R&D and mass-production support facilities: the Third Research Building at the Chemical Research Institute began operations in April 2018, and the Production Technology Center was scheduled to begin operations in summer 2018. - FY2018-Q3RestatedAnnual report
「The Group's R&D expenditure for the cumulative third quarter of the current consolidated fiscal year was ¥4,393 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the current consolidated fiscal year.」
The company continued its R&D activities and reported cumulative R&D expenditure of ¥4,393 million, while stating that there were no material changes in the status of those activities. - FY2018-Q2RestatedAnnual report
「The Group's R&D expenditure for the cumulative second quarter of the current consolidated fiscal year was ¥2,905 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the current consolidated fiscal year.」
The company continued its R&D activities and reported cumulative R&D expenditure of ¥2,905 million, while stating that there were no material changes in the status of those activities. - FY2018-Q1RestatedAnnual report
「The Group's R&D expenditure for the cumulative first quarter of the current consolidated fiscal year was ¥1,500 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company continued its research and development activities and reported cumulative research and development expenses for the quarter, stating that there were no material changes in the status of those activities. - FY2017AdvancedAnnual report
「Lastly, we are also preparing to establish a Chemical Products Production Technology Center to further accelerate the transition from research and development to mass production.」
Regarding the R&D structure, it describes the specific initiative of preparing to establish a Production Technology Center to accelerate the transition from research and development to mass production. - FY2017-Q3RestatedAnnual report
「The amount of research and development activity for the Group as a whole during the cumulative third-quarter period was ¥4,156 million. There were no material changes in the status of the Group's research and development activities during the cumulative third-quarter period.」
The company continued its research and development activities and reported cumulative research and development expenses of ¥4,156 million, stating that there were no material changes in the status of those activities. - FY2017-Q2RestatedAnnual report
「The amount of research and development activity for the Group as a whole during the cumulative second-quarter period was ¥2,927 million. There were no material changes in the status of the Group's research and development activities during the cumulative second-quarter period.」
The company continued its research and development activities and reported cumulative research and development expenses for the quarter, stating that there were no material changes in the status of those activities. - FY2017-Q1RestatedAnnual report
「The amount of research and development activity for the Group as a whole during the cumulative first-quarter period was ¥1,416 million.」
The company continued its research and development activities and reported research and development expenses for the quarter. It states that there were no material changes in the status of its research and development activities. - FY2016First statedAnnual report
「Strengthening the research and development platform with a view to the next 10 years」
The company is also reviewing its research and development themes, narrowing its focus to priority themes and reallocating research personnel.